We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Aeterna Zentaris Inc | NASDAQ:AEZS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.24 | -2.99% | 7.80 | 6.01 | 7.90 | 8.3487 | 7.74 | 7.80 | 19,914 | 21:29:21 |
Edison Investment Research: Aeterna Zentaris - Nearing transition to a commercial story
Aeterna Zentaris is poised to transition to a commercial entity in 2015. Macrilen has an FDA PDUFA date of 5 November in the evaluation of adult growth hormone deficiency (AGHD), a category currently dominated by insulin tolerance tests. Aeterna plans to launch Macrilen in January 2015, if approved. With $39m in cash at 30 June 2014, Aeterna is funded through the reporting of key interim data from its Phase III study of zoptarelin doxorubicin for advanced endometrial cancer, expected near mid-2015.
Aeterna Zentaris is a specialty biopharmaceutical firm developing therapies in oncology and endocrinology. Its lead compounds include zoptarelin doxorubicin, in Phase III trials for endometrial cancer, and Macrilen (macimorelin), under NDA review for adult growth hormone deficiency assessment.
Follow the link to view the full report: http://www.edisoninvestmentresearch.com/research/report/aeterna-zentaris2
Click here to view all of Edison Investment Research's published reports.
1 Year Aeterna Zentaris Chart |
1 Month Aeterna Zentaris Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
